+

US8993542B2 - Methods of treating viral infections - Google Patents

Methods of treating viral infections Download PDF

Info

Publication number
US8993542B2
US8993542B2 US12/864,431 US86443109A US8993542B2 US 8993542 B2 US8993542 B2 US 8993542B2 US 86443109 A US86443109 A US 86443109A US 8993542 B2 US8993542 B2 US 8993542B2
Authority
US
United States
Prior art keywords
hiv
subject
hbv
virus
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/864,431
Other languages
English (en)
Other versions
US20110021464A1 (en
Inventor
Ernest Randall Lanier
Merrick R. Almond
George R. Painter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chimerix Inc
Original Assignee
Chimerix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimerix Inc filed Critical Chimerix Inc
Priority to US12/864,431 priority Critical patent/US8993542B2/en
Assigned to CHIMERIX, INC. reassignment CHIMERIX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALMOND, MERRICK R., LANIER, ERNEST RANDALL, PAINTER, GEORGE R.
Publication of US20110021464A1 publication Critical patent/US20110021464A1/en
Application granted granted Critical
Publication of US8993542B2 publication Critical patent/US8993542B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • HIV-1 Human immunodeficiency virus type 1 (HIV-1) encodes three enzymes which are required for viral replication: reverse transcriptase, protease, and integrase. Combination therapy with protease inhibitors and reverse transcriptase inhibitors has a long record of effectively treating HIV and integrase inhibitors are starting to make significant contributions (See Palella, et al, N. Engl. J. Med., 338, 853-860 (1998); Richman, Nature, 410, 995-1001(2001)). However, therapy frequently fails due to the development of drug resistance, non-compliance with complicated dosing regimens, pharmacokinetic interactions, toxicity, and/or lack of potency. Therefore, there is a continuing need for new therapies that are active against mutant HIV strains, have fewer side effects, and permit simpler dosing schedules.
  • a first aspect of the invention is, in a method of treating a subject for human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection (in some embodiments thereof, said subject has not previously been administered an antiviral active agent for said HIV or HBV infection), the method including: administering said subject an antiviral compound of Formula (I)-(III) and (V)-(X) described herein, or a pharmaceutically acceptable salt, a stereoisomer, a diastereomer, an enantiomer or racemate thereof, in an amount effective to treat said viral infection and substantially inhibit the development of resistance to antiviral compounds in said subject.
  • HBV human immunodeficiency virus
  • HBV hepatitis B virus
  • a further aspect of the invention is, in a method of treating a subject for human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, where said subject has developed resistance, or a toxic response, to at least one antiviral compound in response to prior administration of at least one antiviral compound to said subject for said HIV or HBV infection, the method including: administering said subject an antiviral compound of Formula (I)-(III) and (V)-(X) described herein, or a pharmaceutically acceptable salt, or a stereoisomer, a diastereomer, an enantiomer or racemate thereof, in an amount effective to treat said viral infection and inhibit the further development of resistance to antiviral compounds in said subject.
  • HBV human immunodeficiency virus
  • HBV hepatitis B virus
  • the aforesaid methods may further include concurrently administering said subject one or more additional antiviral active agents with said an antiviral compound.
  • the subject is immunocompromised (e.g., by said virus).
  • the virus is HBV (and in some embodiments thereof, the subject is afflicted with fulminant hepatitis or fulminant hepatic failure).
  • the subject is infected with both HBV and HIV, said antiviral compound is administered in an amount effective to treat both said HBV and HIV.
  • the subject is in utero and said active compound is administered to the mother carrying said subject in utero.
  • a further aspect of the invention is the use of an antiviral compound of Formula (I)-(III) and (V)-(X) described herein as described herein for carrying out a method as described herein, and/or for the preparation of a medicament for carrying out a method as described herein.
  • a further aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising: (a) an antiviral compound of Formula (I)-(III) and (V)-(X) described herein, or pharmaceutically acceptable salt, or a stereoisomer, a diastereomer, an enantiomer or racemate thereof, (b) one or more additional antiviral active agents (e.g., an anti HIV or an anti HBV antiviral compound); and (c) a pharmaceutically acceptable carrier.
  • active compounds described herein associate or bind directly to viruses such as HIV, making possible the delivery of the active compounds into cellular or tissue compartments (sometimes referred to as “privileged compartments”) to which active compounds are not otherwise accessible, and making the active compounds useful as microbicides to inhibit the transmission (e.g., prophylactically) of viruses such as HIV.
  • privileged compartments sometimes referred to as “privileged compartments”
  • Compositions and devices for carrying out such methods, along with the use of active compounds as described herein for carrying out such methods, are also described.
  • the one or more additional antiviral agents can be selected from the group consisting of lamivudine, abacavir, zidovudine, stavudine, zalcitabine, didanosine, emtricitabine, tenofovir, delavirdine, efavirenz, etravirine, nevirapine, amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir, maraviroc, enfuvirtide, and raltegravir.
  • FIG. 1 shows for comparative purposes the virologic response to tenofovir in antiretroviral experienced patients at 24 weeks.
  • FIG. 2 shows the in vitro efficacy of tenofovir (TFV) as compared to HDP-TFV (CMX157).
  • FIG. 3 shows the in vitro efficacy of TFV as compared to HDP-TFV (CMX157), this time with the IC 50 s for HDP-TFV multiplied by 100 for scaling.
  • alkyl refers to a straight or branched chain hydrocarbon containing from 1 to 30 carbon atoms. In some embodiments, the alkyl group contains 2 to 25, 2 to 24, 1 to 10, or 1 to 8 carbon atoms. In some embodiments the alkyl group contains 1 to 6 carbon atoms. In some embodiments, the alkyl group contains 1 to 4 carbon atoms. In still other embodiments, alkyl group contains 1-5 carbon atoms, and in yet other embodiments, alkyl group contain 1-4 or 1-3 carbon atoms.
  • alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like. Additional examples or generally applicable substituents are illustrated by the specific embodiments shown in the Examples which are described herein.
  • alkenyl refers to a straight or branched chain hydrocarbon containing from 2 to 30 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. In some embodiments, the alkenyl group contains 2 to 25, 2 to 24, 2 to 10, 2 to 8 carbon atoms. In some embodiments, the alkenyl group contains 2 to 6 carbon atoms. In still other embodiments, alkenyl groups contain 2-5 carbon atoms, and in yet other embodiments alkenyl groups contain 2-4 or 2-3 carbon atoms.
  • alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, 3-decenyl and the like. Additional examples or generally applicable substituents are illustrated by the specific embodiments shown in the Examples which are described herein.
  • alkynyl refers to a straight or branched chain hydrocarbon group containing from 2 to 30 carbon atoms and containing at least one carbon-carbon triple bond. In some embodiments, the alkynyl group contains 2 to 25, 2 to 24, 2 to 10 or 2 to 8 carbon atoms. In some embodiments, the alkynyl group contains 2 to 6 carbon atoms. In still other embodiments, alkynyl groups contain 2-5 carbon atoms, and in yet other embodiments, alkynyl groups contain 2-4 or 2-3 carbon atoms.
  • alkynyl include, but are not limited, to ethynyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, 1-butynyl and the like. Additional examples or generally applicable substituents are illustrated by the specific embodiments shown in the Examples which are described herein.
  • alkoxy refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom.
  • the alkyl group contains 1-30 carbon atoms. In other embodiment, the alkyl group contains 1-20, 1-10 or 1-5 carbon atoms. In some embodiments, the alkoxyl group contains 1 to 8 carbon atoms. In some embodiments, the alkoxyl group contains 1 to 6 carbon atoms. In some embodiments, the alkoxyl group contains 1 to 4 carbon atoms. In still other embodiments, alkoxyl group contains 1-5 carbon atoms, and in yet other embodiments, alkoxyl group contain 1-4 or 1-3 carbon atoms.
  • alkoxyl include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, and n-pentoxy. Additional examples or generally applicable substituents are illustrated by the specific embodiments shown in the Examples which are described herein.
  • amino acid residue refers to a compound consisting of a carbon atom which is bonded to a primary amino (—NH 2 ) group, a carboxylic acid (—COOH) group, a side chain, and a hydrogen atom.
  • amino acid includes, but is not limited to, Glycine, Alanine, Valine, Leucine, Isoleucine, Serine, Threonine, Aspartic acid and Glutamic acid.
  • R 2 is —NR′H and R′ is an amino acid residue
  • N is attached to the carbon atom as a side chain.
  • amino acid also includes derivatives of amino acids such as esters, and amides, and salts, as well as other derivatives, including derivatives having pharmacoproperties upon metabolism to an active form. Additional examples or generally applicable substituents are illustrated by the specific embodiments shown in the Examples which are described herein.
  • cycloalkyl refers to a monovalent saturated cyclic or bicyclic hydrocarbon group of 3-12 carbons derived from a cycloalkane by the removal of a single hydrogen atom. In some embodiments, cycloalkyl contains 3 to 8 carbon atoms. In some embodiments, cycloalkyl contains 3 to 6 carbon atoms. Cycloalkyl groups may be optionally substituted with alkyl, alkoxy, halo, or hydroxy substituents.
  • cycloalkyl include, but are not limited to, are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.
  • heteroalkyl refers to alkyl, alkenyl or alkynyl groups which contain one or more oxygen, sulfur, nitrogen, phosphorus or silicon atoms, e.g., in place of carbon atoms.
  • the heteroalkyl group contains 1-8 carbon atoms.
  • the heteroalkenyl and heteralkynyl groups independently contain 2-8 carbon atoms.
  • heteroalkyl, heteroalkenyl and heteralkynyl independently contain 2-5 carbon atoms, and in yet other embodiments, heteroalkyl, heteroalkenyl and heteralkynyl independently contain 2-4 or 2-3 carbon atoms.
  • heterocycle or “heterocyclyl” represent a 3-, 4-, 5-, 6-, 7- or 8-membered saturated or unsaturated ring containing one, two or three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
  • the heterocycle contains 3, 4, 5, or 6 carbons.
  • heterocyclyl include, but not limited to, furanyl, thiophenyl, pyrrolyl, piperidinyl, 1,4-dioxanyl, morpholinyl, thiomorpholinyl, pyrolidinyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyrazolinyl, isoxazolyl, isothiazolyl, and piperazinyl,
  • halogen refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) and the term “halo” refers to the halogen radicals: fluoro (—F), chloro (—Cl), bromo (—Br), and iodo (—I).
  • haloalkyl refers to a straight or branched chain alkyl group as defined herein containing at least one carbon atoms substituted with at least one halo group, halo being as defined herein.
  • the haloalkyl contains 1 to 30 carbon atoms.
  • the halkalkyl contains 1 to 8 or 1 to 6 carbon atoms.
  • the haloalkyl contains 1 to 4 carbon atoms. Additional examples or generally applicable substituents are illustrated by the specific embodiments shown in the Examples which are described herein.
  • aryl refers to a monocyclic carbocyclic ring system or a bicyclic carbocyclic fused ring system having one or more aromatic rings.
  • Representative examples of aryl include, azulenyl, indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, and the like.
  • aryl is intended to include both substituted and unsubstituted aryl unless otherwise indicated.
  • an aryl may be substituted with one or more heteroatoms (e.g., oxygen, sulfur and/or nitrogen). Additional examples or generally applicable substituents are illustrated by the specific embodiments shown in the Examples which are described herein.
  • Subjects to be treated by the methods of the present invention are, in general, mammalian and primate subjects (e.g., human, monkey, ape, chimpanzee).
  • Subjects may be male or female and may be of any age, including prenatal (i.e., in utero), neonatal, infant, juvenile, adolescent, adult, and geriatric subjects. Thus, in some cases the subjects may be pregnant female subjects.
  • Treatment may be for any purpose, including the therapeutic treatment of previously infected subjects, as well as the prophylactic treatment of uninfected subjects (e.g., subjects identified as being at high risk for infection).
  • Human immunodeficiency virus (or “HIV”) as used herein is intended to include all subtypes thereof, including HIV subtypes A, B, C, D, E, F, G, and O, and HIV-2.
  • Hepatitis B virus (or “HBV”) as used herein is intended to include all subtypes (adw, adr, ayw, and ayr) and or genotypes (A, B, C, D, E, F, G, and H) thereof.
  • Multi-nucleoside resistant or “multi-nucleoside resistant” as used herein refers to genotypic or phenotypic patterns which predict or indicate diminished efficacy for most or all nucleoside and nucleotide reverse transcriptase inhibitors.
  • Genotypic examples include the Q151M complex, the T69SXX complex and multiple thymidine analog associated mutations.
  • Phenotypic examples include patterns where few or no NRTIs test as “sensitive”.
  • Toxic response may be any deleterious toxic and/or undesired response to a treatment with an antiviral agent, including but not limited to nausea, vomiting, rash, diarrhea, nephrotoxicity, mitochondrial toxicity, etc. and combinations thereof.
  • a “therapeutically effective amount” or “an amount effective” refers to an amount that will provide some alleviation, mitigation, and/or decrease in at least one clinical symptom in the subject. Those skilled in the art will appreciate that the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder as described herein.
  • treatment may be administered after one or more symptoms have developed.
  • treatment may be administered in the absence of symptoms.
  • treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
  • Active compounds of the present invention may optionally be administered in conjunction with other active compounds and/or agents useful in the treatment of viral infections as described herein.
  • the other compounds may optionally be administered concurrently.
  • concurrently means sufficiently close in time to produce a combined effect (that is, concurrently may be simultaneously, or it may be two or more events occurring within a short time period before or after each other).
  • Active compounds useful for carrying out the present invention are, in general, antiviral compounds of Formula I (or in some embodiments more particularly compounds of Formula Ia), or a pharmaceutically acceptable salt, or a stereoisomer, a diastereomer, an enantiomer or racemate thereof:
  • B is a purine or pyrimidine base, including but not limited to: adenine, 6-chloropurine, xanthine, hypoxanthine, guanine, 8-bromoguanine, 8-chloroguanine, 8-aminoguanine, 8-hydrazinoguanine, 8-hydroxyguanine, 8-methylguanine, 8-thioguanine, 2-aminopurine, 2,6-diaminopurine, thymine, cytosine, 5-fluorocytosine, uracil; 5-bromouracil, 5-iodouracil, 5-ethyluracil, 5-ethynyluracil, 5-propynyluracil, 5-propyluracil, 5-vinyluracil, 5-bromovinyluracil;
  • R 1 is H, methyl, ethyl, —CH 2 OH, —CH 2 CH 2 OH, —CH(OH)CH 3 , or C 1-6 haloalkyl;
  • R 2 is fluoro, hydroxy, —OR 2a , —BH 3 , C 1 -C 8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 1-8 heteroalkyl, C 2-8 heteroalkenyl, C 2-8 heteroalkynyl, or —NR′H;
  • R 3 is —O(CH 2 ) m O(CH 2 ) n CH 3 , where m is from 2 to 5 (in some embodiments, 2 or 3) and n is from 11 to 21 (in some embodiments, 15 or 17); and
  • X is selenium, sulphur, or oxygen (in some embodiments, oxygen)
  • base B includes, but are not limited to, compounds of the general formula:
  • Y is N or CX
  • R 11 is selected from the group consisting of H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or C 6-10 aryl, and carbonyl substituted with a C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or C 6-10 aryl.
  • B is further described in U.S. Pat. No. 6,583,149, which is incorporated by reference in its entirety.
  • base B includes, but are not limited to, compounds of the general formula:
  • Z is NH 2 or hydroxyl
  • L 2 is a covalent bond (that is, is absent), —N(—R 15 )—, N(—R 15 )C( ⁇ O)—, —O—, —S—, —S( ⁇ O)—, or is —S( ⁇ O) 2 —,
  • R 13 is H, C 1-6 alkyl, C 1-6 heteroalkyl, C 2-6 alkenyl, C 6-10 aryl, C 7-16 arylalkyl, C 3-10 carbocyclyl, C 6-10 heterocyclyl, or C 7-16 heterocyclylalkyl;
  • R 14 is H, halo, hydroxy, alkoxy, —O(CH 2 ) x OC( ⁇ O)OR 15 , or OC( ⁇ O)OR 15 , wherein X is 2 or 3 to 10, 15 or 20, and
  • R 15 is H, C 1-6 alkyl, C 1-6 heteroalkyl, C 2-6 alkenyl, C 6-10 aryl, C 7-16 arylalkyl, C 3-10 cyclyl, C 6-10 heterocyclyl, or C 7-16 heterocyclylalkyl.
  • base B includes, but not limited to, compounds of the general formula:
  • R 16 and R 17 are independently selected from the group consisting of hydrogen, C 1-6 alkyl, or C 3-6 cycloalkyl, or N, R 16 and R 17 taken together to form N 3 , C 3-8 heterocyclyl, wherein C 3-6 cycloalkyl and C 3-8 heterocyclyl can be optionally substituted with one or more C 1-5 alkyl.
  • Exemplary active compounds (tenofovir analogs) useful for carrying out the present invention include, but are not limited to:
  • active compounds for carrying out the present invention include, but are not limited to:
  • active compounds for carrying out the present invention include, but are not limited to:
  • active compounds useful for carrying out the present invention include lipid tenofovir conjugates such as compounds of Formula II (or in some embodiments, more particularly as compounds of Formula IIa):
  • n is from 11 to 21 (in some embodiments, 15 or 17), or a pharmaceutically acceptable salt, or a stereoisomer, a diastereomer, an enantiomer or racemate thereof.
  • CMX157 a compound of Formula III (also referred to as CMX157 herein):
  • 6,716,825 to Hostetler can be prepared by modification of known techniques including but not limited to those described in PCT Patent Applications WO2005/79812 A1 (Anadys Pharmaceuticals) and WO2008/10921 A2 (Gilead).
  • the active agents have the following structures:
  • W 1 , W 2 , and W 3 are each independently —O—, —S—, —SO—, —SO 2 , —O(C ⁇ O)—, —(C ⁇ O)O—, —NH(C ⁇ O)—, —(C ⁇ O)NH— or —NH—; and in one embodiment are each independently O, S, or —O(C ⁇ O)—;
  • R 1 is an optionally substituted alkyl, alkenyl or alkynyl, e.g., C 1-30 alkyl, C 2-30 alkenyl, or C 2-30 alkynyl; or in one embodiment, R 1 is optionally substituted C 8-30 alkyl, C 8-30 alkenyl or C 8-30 alkynyl, or R 1 is a C 8-24 alkyl, C 8-24 alkenyl or C 8-24 alkynyl (e.g., C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , or C 24 alkyl, alkenyl, or alkynyl);
  • R 2 and R 3 are each independently an optionally substituted C 1-25 alkyl, C 2-25 alkenyl, or C 2-25 alkynyl;
  • D may be tenofovir directly linked to a methylene group as depicted in Formulas V-X, e.g., D is a moiety of the formula:
  • Tenofovir is directly linked to the methylene group of formula V-X via the phosphonate hydroxyl group.
  • the active compound has one of the following structures: wherein R 1 is an optionally substituted C 8-24 alkyl, for example, C 12-24 alkyl, D is tenofovir linked directly to a methylene group as depicted in Formulas V-X.
  • the active compounds disclosed herein can, as noted above, be provided in the form of their pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects.
  • Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid,
  • Active compounds as described herein can be prepared in accordance with known procedures, or variations thereof that will be apparent to those skilled in the art. See, e.g., Painter et al., Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections, Antimicrobial Agents and Chemotherapy 51, 3505-3509 (2007) and US Patent Application Publication No. 2007/0003516 to Almond et al.
  • Additional antiviral active agents that may be used in carrying out the present invention include HIV-protease inhibitors, nucleoside reverse transcriptase inhibitors (this term herein including nucleotide reverse transcriptase inhibitors), non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, entry inhibitors, fusion inhibitors, maturation inhibitors, and combinations thereof.
  • nucleoside reverse transcriptase inhibitors this term herein including nucleotide reverse transcriptase inhibitors
  • non-nucleoside reverse transcriptase inhibitors include integrase inhibitors, entry inhibitors, fusion inhibitors, maturation inhibitors, and combinations thereof.
  • Numerous examples are known and described in, for Example, US Patent Application Publication No. 2006/0234982 to Dahl et al. at Table A therein, and in Table A as set forth below.
  • Additional examples include, but are not limited to the integrase inhibitor Isentress or raltegravir (MK-0518: Merck), the CCR5 inhibitor Maraviroc or selzentry (and K-427857, Pfizer) and others of these classes.
  • NRTI non-nucleoside reverse transcriptase inhibitor 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H3,1-benzoxazin-2-one, and pharmaceutically acceptable salts thereof, are described in, for example, U.S. Pat. No. 5,519,021.
  • Examples of the present invention include efavirenz.
  • NRTI nucleoside reverse transcriptase inhibitor
  • FTC 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
  • pharmaceutically acceptable salts thereof are described in, for example, U.S. Pat. No. 6,642,245 to Liotta et al.
  • examples of the present invention include emtricitabine.
  • Integrase inhibitors include but are not limited to those described in US Patent Application Publication No. 2007/0072831, WO 02/30426, WO 02/30930, WO 02/30931, WO 02/055079, WO 02/36734, U.S. Pat. No. 6,395,743; U.S. Pat. No. 6,245,806; U.S. Pat. No. 6,271,402; WO 00/039086; WO 00/075122; WO 99/62513; WO 99/62520; WO 01/00578; Jing, et al., Biochemistry, 41, 5397-5403, (2002); Pais, et al., J. Med.
  • compositions examples include but are not limited to those described in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co. (1990) (See also US Patent Application US 2007/0072831).
  • the compounds of the invention may be formulated with conventional carriers, diluents and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders, diluents and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. Formulations optionally contain excipients such as those set forth in the “Handbook of Pharmaceutical Excipients” (1986) and include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like.
  • Compounds of the invention and their physiologically acceptable salts may be administered by any route appropriate to the condition to be treated, suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural).
  • suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural).
  • the preferred route of administration may vary with for example the condition of the recipient.
  • the formulations both for veterinary and for human use, of the present invention comprise at least one active ingredient, as above defined, together with one or more pharmaceutically acceptable carriers (excipients, diluents, etc.) thereof and optionally other therapeutic ingredients.
  • the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • the formulations are, in some embodiments, applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc), in some embodiments, 0.2 to 15% w/w and in other embodiments, 0.5 to 10% w/w.
  • the active ingredients may be employed with either a paraffinic or a water-miscible ointment base.
  • the active ingredients may be formulated in a cream with an oil-in-water cream base.
  • the aqueous phase of the cream base may include, for example, at least 30% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG400) and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs.
  • the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. In some embodiments, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. In some embodiments, it includes both an oil and a fat.
  • the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax
  • the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • Emulgents and emulsion stabilizers suitable for use in the formulation of the present invention include TweenTM 60, SpanTM 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulfate.
  • the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
  • Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • the active ingredient is present in such formulations in a concentration of 0.5 to 20%.
  • the active ingredient is present in a concentration of 0.5 to 10%.
  • the active ingredient is present in a concentration of about 1.5% w/w.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc), which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops include aqueous or oily solutions of the active ingredient.
  • Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as pentamidine for treatment of pneumocystis pneumonia.
  • Formulations suitable for vaginal administration may be presented as pessaries, rings, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • the present invention further provides veterinary compositions comprising at least one active ingredient as above defined together with a veterinary carrier
  • Veterinary carriers are materials useful for the purpose of administering the composition and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in the veterinary art and are compatible with the active ingredient. These veterinary compositions may be administered orally, parenterally or by any other desired route.
  • Controlled release formulations adapted for oral administration in which discrete units comprising one or more compounds of the invention can be prepared according to conventional methods.
  • Controlled release formulations may be employed for the treatment or prophylaxis of various microbial infections particularly human bacterial, human parasitic protozoan or human viral infections caused by microbial species including Plasmodium, Pneumocystis, herpes viruses (CMV, HSV 1, HSV 2, VZV, and the like), retroviruses, adenoviruses and the like.
  • the controlled release formulations can be used to treat HIV infections and related conditions such as tuberculosis, malaria, pneumocystis pneumonia, CMV retinitis, AIDS, AIDS-related complex (ARC) and progressive generalized lymphadeopathy (PGL), and AIDS-related neurological conditions such as multiple sclerosis, and tropical spastic paraparesis.
  • human retroviral infections that may be treated with the controlled release formulations according to the invention include Human T-cell Lymphotropic virus and HIV-2 infections.
  • the invention accordingly provides pharmaceutical formulations for use in the treatment or prophylaxis of the above-mentioned human or veterinary conditions and microbial infections.
  • the compounds of the invention may be employed in combination with pharmacokinetic enhancers (sometimes also referred to as “booster agents”).
  • pharmacokinetic enhancers sometimes also referred to as “booster agents”.
  • One aspect of the invention provides the use of an effective amount of an enhancer to enhance or “boost” the pharmacokinetics of a compound of the invention.
  • An effective amount of an enhancer for example, the amount required to enhance an active compound or additional active compound of the invention, is the amount necessary to improve the pharmacokinetic profile or activity of the compound when compared to its profile when used alone. The compound possesses a better efficacious pharmacokinetic profile than it would without the addition of the enhancer.
  • the amount of pharmacokinetic enhancer used to enhance the potency of the compound is, preferably, subtherapeutic (e.g., dosages below the amount of booster agent conventionally used for therapeutically treating infection in a patient).
  • An enhancing dose for the compounds of the invention is subtherapeutic for treating infection, yet high enough to effect modulation of the metabolism of the compounds of the invention, such that their exposure in a patient is boosted by increased bioavailability, increased blood levels, increased half life, increased time to peak plasma concentration, increased/faster inhibition of HIV integrase, RT or protease and/or reduced systematic clearance.
  • RITONAVIRTM Abbott Laboratories.
  • compositions of the present invention can include the active compounds as described in section A above in combination with one or more (e.g., 1, 2, 3) additional active agents such as described in section B above, in analogous manner as known in the art.
  • additional active agents such as described in section B above
  • combinations of efavirenz (an NRTI), emtricitabine (an NNRTI) and tenofovir DF (an NRTI) are described in, for example, Dahl et al., US Patent Application Publication No. 2007/0099902 to Dahl et al.
  • Specific examples of such combinations include, but are not limited to: CMX 157 or a pharmaceutically acceptable salt) in combination with:
  • active agents of the present invention surprisingly associate or bind to viral particles. Since viral particles migrate or permeate into cellular or tissue compartments that are not generally accessible to active therapeutic agents (thus creating a substantially untreated “reservoir” of infection when subjects are systemically administered such agents), this finding makes possible (a) the treatment of infection in such privileged compartments, and (b) the use of active agents in prophylactic or microbicidal treatments (where association or binding of the active agent to virus before infection occurs is of therapeutic benefit).
  • a privileged compartment is a cellular or tissue compartment to which said virus permeates in vivo, to which said active agent does not efficiently permeate in vivo in the absence of said virus, and to which said active agent is carried in vivo by said virus when said active agent binds to said virus.
  • the privileged compartment when it is a tissue compartment, it may be brain (central nervous system), lymphoid, or testes.
  • cellular privileged compartments include but are not limited to dendritic cells, microglia, monocyte/macrophages, and combinations thereof.
  • Compositions and methods of treating privileged compartment infections may be prepared and carried out as described above. Prophylactic compositions, devices and methods are discussed in further detail below.
  • the present invention can take the form of a topical compositions containing the active agents described herein for inhibiting or combating viral infection, e.g., for prophylactic use.
  • Such compositions (with active agents other than those disclosed herein) are known and described in, for example, U.S. Pat. No. 6,545,007, the disclosure of which is incorporated herein by reference in its entirety.
  • compositions can take several forms.
  • the composition is in the form of a cream, lotion, gel, or foam that is applied to the affected skin or epithelial cavity, and preferably spread over the entire skin or epithelial surface which is at risk of contact with bodily fluids.
  • Such formulations which are suitable for vaginal or rectal administration, may be present as aqueous or oily suspensions, solutions or emulsions (liquid formulations) containing in addition to the active ingredient, such carriers as are known in the art to be appropriate.
  • lubricants i.e., lubricants that are not pre-packaged with condoms
  • gels and similar aqueous formulations are generally preferred, for various reasons (both scientific and economic) known to those skilled in the art. These formulations are useful to protect not only against sexual transmission of HIV, but also to prevent infection of a baby during passage through the birth canal. Thus the vaginal administration can take place prior to sexual intercourse, during sexual intercourse, and immediately prior to childbirth.
  • One method of applying an antiviral lubricant to the genitals involves removing a small quantity (such as a teaspoon, or several milliliters) of a gel, cream, ointment, emulsion, or similar formulation from a plastic or metallic tube, jar, or similar container, or from a sealed plastic, metallic or other packet containing a single dose of such composition, and spreading the composition across the surface of the penis immediately before intercourse.
  • a small quantity such as a teaspoon, or several milliliters
  • Alternate methods of emplacement include: (1) spreading the composition upon accessible surfaces inside the vagina or rectum shortly before intercourse; and (2) emplacing a condom, diaphragm, or similar device, which has already been coated or otherwise contacted with an anti-viral lubricant, upon the penis or inside the vagina.
  • any of these methods of spreading an anti-viral lubricant across the surfaces of the genitals causes the lubricant to coat and remain in contact with the genital and epithelial surfaces throughout intercourse.
  • compositions are used in conjunction with condoms, to enhance the risk-reducing effectiveness of condoms and provide maximum protection for users.
  • the composition can either be coated onto condoms during manufacture, and enclosed within conventional watertight plastic or foil packages that contain one condom per package, or it can be manually applied by a user to either the inside or the outside of a condom, immediately before use.
  • “condom” refers to a barrier device which is used to provide a watertight physical barrier between male and female genitalia during sexual intercourse, and which is removed after intercourse.
  • This term includes conventional condoms that cover the penis; it also includes so-called “female condoms” which are inserted into the vaginal cavity prior to intercourse.
  • the term “condom” does not include diaphragms, cervical caps or other barrier devices that cover only a portion of the epithelial membranes inside the vaginal cavity.
  • condoms should be made of latex or a synthetic plastic material such as polyurethane, since these provide a high degree of protection against viruses.
  • the composition is in the form of an intra-vaginal pill, an intra-rectal pill, or a suppository.
  • the suppository or pill should be inserted into the vaginal or rectal cavity in a manner that permits the suppository or pill, as it dissolves or erodes, to coat the vaginal or rectal walls with a prophylactic layer of the anti-HIV agent.
  • the composition is topically applied by release from an intravaginal device.
  • Devices such as vaginal rings, vaginal sponges, diaphragms, cervical caps, female condoms, and the like can be readily adapted to release the composition into the vaginal cavity after insertion.
  • compositions used in the methods of this invention may also comprise additional active agents, such as another agent(s) to prevent HIV infection, and agents that protect individuals from conception and other sexually transmitted diseases.
  • additional active agents such as another agent(s) to prevent HIV infection, and agents that protect individuals from conception and other sexually transmitted diseases.
  • the compositions used in this invention further comprise one or more additional anti-HIV agents, virucides effective against viral infections other than HIV, and/or spermicides.
  • the composition contains nonoxynol, a widely-used spermicidal surfactant.
  • the resulting composition could be regarded as a “bi-functional” composition, since it would have two active agents that provide two different desired functions, in a relatively inert carrier liquid; the nonoxynol would provide a spermicidal contraceptive agent, and the DABO would provide anti-viral properties.
  • the nonoxynol is likely to cause some level of irritation, in at least some users; this is a regrettable but is a well-known side effect of spermicidal surfactants such as nonoxynol and octoxynol, which attack and destroy the lipid bilayer membranes that surround sperm cells and other mammalian cells.
  • compositions used in this invention may also contain a lubricant that facilitates application of the composition to the desired areas of skin and epithelial tissue, and reduces friction during sexual intercourse.
  • a lubricant that facilitates application of the composition to the desired areas of skin and epithelial tissue, and reduces friction during sexual intercourse.
  • the lubricant can be applied to the exterior of the dosage form to facilitate insertion.
  • the invention provides a device for inhibiting the sexual transmission of HIV comprising (a) a barrier structure for insertion into the vaginal cavity, and (b) a composition comprising an active agent as described herein.
  • a barrier structure for insertion into the vaginal cavity
  • a composition comprising an active agent as described herein.
  • preferred devices which act as barrier structures, and which can be adapted to apply anti-HIV agent include the vaginal sponge, diaphragm, cervical cap, or condom (male or female).
  • compositions and devices of this invention can be adapted generally to release active agent in a time sensitive manner that best corresponds to the timing of sexual activity.
  • the compositions When topically applied as a lotion or gel, the compositions are preferably applied immediately prior to sexual activity.
  • Other modes of application, such as devices and suppositories, can be designed to release active agent over a prolonged period of time, at a predetermined rate, depending upon the needs of the consumer.
  • FIG. 1 demonstrates, for comparative purposes, the virologic response to tenofovir in antiretroviral experienced patients at 24 weeks. Data is from M. Miller et al. J Infect Dis. 189: 837 (2004). The viral load response in monotherapy with TDF in na ⁇ ve patients is ⁇ 1.5 log (Louie et al, Determining the antiviral activity of tenofovir disoproxil fumarate in treatment - naive chronically HIV -1- infected individuals , AIDS, 17, 1151 (2003)).
  • FIGS. 2-3 show the in vitro efficacy of tenofovir (TFV) as compared to HDP-TFV (CMX157) in a PHENOSENSETM HIV assay (service available from Monogram Biosciences, Inc., 345 Oyster Point Blvd., South San Francisco, Calif. 94080-1913 USA.)
  • TFV tenofovir
  • CMX157 HDP-TFV
  • PHENOSENSETM HIV assay service available from Monogram Biosciences, Inc., 345 Oyster Point Blvd., South San Francisco, Calif. 94080-1913 USA.
  • the IC 50 s for CMX157 are multiplied by 100 for scaling. Results are also shown in Table 1 below (where ABC is abacavir FTC is emtricitabine, ddI is didanosine, 3TC is lamivudine, d4T is stavudine, TFV is tenofovir and ZDV is zidovudine).
  • CMX157 is active against all major HIV subtypes (A-G, O and HIV-2) with IC 50 s ranging from 0.2-7.2 nanomolar.
  • Pharmacokinetic parameters were estimated using mean data from one male and one female in each group at each time point.
  • AUC 0-24 AUC from 0 to 24 h; t 1/2elim, elimination half-life; ND, not determined (See G. Painter et al., Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections, Antimicrobial Agents and Chemotherapy 51, 3505-3509 (2007).)
  • CMX157 To examine the potential of CMX157 to associate directly with virus, concentrated HIV-1 IIIB (approximately 9.7 ⁇ 10 10 virus particles) is treated with 500 nM CMX157 or TFV for 2 hours. Following incubation, virus is pelleted to remove unbound compound, lysed with 70% ice cold methanol and centrifuged. Supernatants are analyzed in triplicate using LC/MS/MS (liquid chromatography/mass spectrometry). TFV, TFV mono- and diphosphate are separated by gradient, reverse phase, ion-paring chromatography and detected by positive ion electrospray. The levels of CMX157 associated with the viral pellets ( ⁇ 37,000 molecules/virion) are much higher than the levels of TFV associated with viral pellets ( ⁇ 100 molecules/virion).
  • CMX157 To evaluate the effect of exposing purified virus to drug on TCID 50 , concentrated HIV-1 IIIB virus (approximately 9.7 ⁇ 10 10 virus particles) is treated with 1000, 500, 250 or 125 nM CMX157 or TFV for 2 hours. As shown in Table 5, CMX157 consistently reduce viral replication 2-4 fold across this dose range while TFV has no discernible effect even at the highest dose.
  • CMX157 decreases infectivity following 1 minute incubation prior to centrifugation.
  • TCID 50 values are measured by XTT, RT and p24.
  • HDP-ACV is evaluated in parallel to determine if a lipid-nucleotide of similar structure but without HIV activity would have any effect in this assay.
  • the TCID 50 results of these assays are summarized in Table 7.
  • CMX157 associated with HIV-1 IIIB using lower concentrations of test material yielded a dose response indicating concentrations of 3.9 nM and greater resulted in reduced infectivity.
  • the XTT and p24 endpoints for measuring TCID 50 yielded greater fold decreases in infectivity compared to the RT endpoint as might be expected for a NRTI in this system.
  • HDP-ACV had no effect on infectious virus when incubated with HIV-1 IIIB at the concentrations evaluated.
  • CMX157 associates directly with HIV and that this association reduces viral replication.
  • Incubation of HIV with low nanomolar concentrations of CMX157 for short periods of time (1-15 minutes) resulted in decreased viral production in vitro.
  • No effect on viral replication is seen for TFV or the lipid control, HDP-ACV.
  • CMX157 may have advantages over TFV via this mechanism of cell targeting as any HIV exposed to CMX157 will then carry its own antiviral to whatever compartment or cell type it subsequently enters.
  • CMX157 lipid-TFV drug invokes direct association of the CMX157 lipid-TFV drug with HIV followed by delivery of CMX157 by the virus to the cell being infected.
  • the data presented herein demonstrates a significant difference (approximate 300 fold) in the level of CMX157 directly associated with purified HIV versus TFV.
  • pre-incubation of HIV with CMX157 inhibited replication of HIV in cells that are not exposed to drug except via the virus itself; pre-incubation of HIV with TFV has no inhibitory effect on subsequent HIV replication, consistent with the low levels of TFV associated with isolated virions.
  • NERT natural endogenous reverse transcription
  • CMX157 The anti-HIV-1 activity of CMX157 is evaluated in two-drug combination studies with twenty-four different FDA-approved anti-HIV inhibitors. Each two-drug combination is tested three times in CEM T-lymphocytic cells or MAGI-CCR5 cells acutely infected with the laboratory-adapted strain HIV-1 IIIB or HIV-1 Ba-L , respectively. Viral growth/inhibition is evaluated by measuring virus-induced cytopathic effects (CPE) in CEM cells or by ⁇ -galactosidase reporter gene induction in MAGI-CCR5 cells at the experimental endpoint. The cytotoxicity of each two-drug combination is also evaluated in parallel with the antiviral evaluations.
  • CPE virus-induced cytopathic effects
  • concentrations of CMX157 used in these evaluations are selected in order to test a broad range of concentrations and to provide as complete a dose response curve as possible under the limitations of eight total concentrations.
  • concentrations of lamivudine, abacavir, zidovudine, stavudine, zalcitabine, didanosine, emtricitabine, tenofovir, delavirdine, efavirenz, etravirine, nevirapine, amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir, maraviroc, enfuvirtide, and raltegravir are selected to provide as complete of a dose response curve as possible under the limitations of five total concentrations.
  • synergy is defined as drug combinations yielding synergy volumes greater than 50. Slightly synergistic activity and highly synergistic activity have been operationally defined as yielding synergy volumes of 50-100 and >100, respectively. Additive drug interactions have synergy volumes in the range of ⁇ 50 to 50, while synergy volumes between ⁇ 50 and ⁇ 100 are considered slightly antagonistic and those ⁇ 100 are highly antagonistic.
  • IC 50 50% inhibitory concentrations
  • CMX-157 is determined to have additive or synergistic interactions for all two-drug combinations performed with FDA-approved antiretroviral drugs. None of the interactions is found to be antagonistic. This conclusion of additive to synergistic interactions for all combinations is also reached when assessing the interactions at the IC 50 range of the two drugs from each combination. In contrast, the positive antagonism control of stavudine in combination with ribavirin resulted in antagonistic interactions as expected.
  • NTP Nucleoside Reverse Transcriptase Inhibitors
  • Lamivudine (3TC) Slightly Synergistic Abacavir (ABC) Additive Zidovudine (AZT) Additive Stavudine (d4T) Additive Zalcitabine (ddC) Highly Synergistic Didanosine (ddI) Additive Emtricitabine (FTC) Slightly Synergistic Tenofovir (TFV) Additive Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) Delavirdine (DLV) Slightly Synergistic Efavirenz (EFV) Slightly Synergistic Etravirine (ETV) Slightly Synergistic Nevirapine (NVP)
  • CMX157 No antagonistic interactions were observed within the concentration ranges examined for antiviral efficacy between CMX157 and the twenty-four FDA-approved antiretroviral drugs.
  • a highly synergistic interaction is observed between CMX157 and zalcitabine, and slightly synergistic interactions were observed with lamivudine, emtricitabine, delavirdine, efavirenz, etravirine, amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, tipranavir, and maraviroc, suggesting possible beneficial interactions with these drugs.
  • CMX157 interactions with the remaining drugs resulted in strictly additive results.
  • the signature mutation for tenofovir is K65R, which is generally associated with a 2 to 4 fold increase in IC 50 for tenofovir and lack of clinical response to Viread.
  • TFV tenofovir
  • In vitro studies designed to select CMX157 resistant mutants use wild-type HIV-1 as the primary inoculum and TFV as a positive control. These studies are conducted by serial passage of HIV-1 IIIB and HIV-1RF in CEM-SS cells using increasing concentrations of TFV or CMX157. Drug levels are increased following detection of viral growth at each passage using procedures known to one skilled in the art. Upon completion of each passage, the reverse transcriptase coding region of the viral genome is sequenced to identify any possible resistance-associated mutations that may have emerged within the virus pool.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US12/864,431 2008-01-25 2009-01-23 Methods of treating viral infections Active 2030-09-06 US8993542B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/864,431 US8993542B2 (en) 2008-01-25 2009-01-23 Methods of treating viral infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2363308P 2008-01-25 2008-01-25
US10181008P 2008-10-01 2008-10-01
PCT/US2009/000447 WO2009094190A2 (fr) 2008-01-25 2009-01-23 Méthodes de traitement d’infections virales
US12/864,431 US8993542B2 (en) 2008-01-25 2009-01-23 Methods of treating viral infections

Publications (2)

Publication Number Publication Date
US20110021464A1 US20110021464A1 (en) 2011-01-27
US8993542B2 true US8993542B2 (en) 2015-03-31

Family

ID=40901582

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/864,431 Active 2030-09-06 US8993542B2 (en) 2008-01-25 2009-01-23 Methods of treating viral infections

Country Status (12)

Country Link
US (1) US8993542B2 (fr)
EP (2) EP2254582B1 (fr)
JP (1) JP5562255B2 (fr)
CN (3) CN105055432A (fr)
AU (1) AU2009206673B2 (fr)
CA (1) CA2713105C (fr)
ES (1) ES2572631T3 (fr)
HK (2) HK1151237A1 (fr)
IL (2) IL207170A (fr)
MX (1) MX2010008148A (fr)
WO (2) WO2009094191A2 (fr)
ZA (1) ZA201005737B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044281A1 (fr) 2014-09-15 2016-03-24 The Regents Of The University Of California Analogues nucléotidiques
US20160158259A1 (en) * 2010-04-26 2016-06-09 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
WO2017048956A1 (fr) 2015-09-15 2017-03-23 The Regents Of The University Of California Analogues nucléotidiques
US9775852B2 (en) 2013-03-15 2017-10-03 The Regents Of The University Of California Acyclic nucleoside phosphonate diesters

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
EP2869823A4 (fr) * 2012-07-03 2016-03-16 Chimerix Inc Procédé de traitement des infections rétrovirales et posologies associées
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US20150322413A1 (en) 2012-11-27 2015-11-12 Saint Louis University Hbv rnase h purification and enzyme inhibitors
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
CN106061982A (zh) * 2013-12-05 2016-10-26 奇默里克斯公司 支链无环核苷膦酸酯及其合成方法与应用
CN107849074A (zh) * 2016-01-19 2018-03-27 四川海思科制药有限公司 一种核苷类似物的烷氧烷基酯前药及其应用
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ウイルス薬を送達するための薬物送達システム
US20180296588A1 (en) 2017-04-14 2018-10-18 Contravir Pharmaceuticals, Inc. Combination therapy for treating viral infections
TW201912153A (zh) * 2017-08-30 2019-04-01 加拿大商愛彼特生物製藥公司 用於治療ｂ型肝炎的化合物、醫藥組合物及方法

Citations (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1944530A (en) 1929-04-08 1934-01-23 Ig Farbenindustrie Ag Phosphoric acid esters
US3422021A (en) 1963-03-18 1969-01-14 Procter & Gamble Detergent composition
US3468935A (en) 1964-11-11 1969-09-23 Albright & Wilson Mfg Ltd Preparation of organophosphonic acids
GB1280788A (en) 1970-02-27 1972-07-05 Thomae Gmbh Dr K 3-octadecyloxypropyl-2'-trimethylammonium-ethyl phosphate
US4327039A (en) 1979-10-27 1982-04-27 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Process for the production of 3-amino-1-hydroxypropane-1,1-diphosphonic acid
CS220713B1 (cs) 1981-06-02 1983-04-29 Antonin Holy Dialkylestery kyseliny p-toluensulfonyloxymethanfosfonové a způsob jejich přípravy
US4444766A (en) 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
US4562179A (en) 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
EP0186405A2 (fr) 1984-12-21 1986-07-02 The Procter & Gamble Company Compositions pharmaceutiques contenant des diphosphonates géminaux
JPS61152694A (ja) 1984-12-27 1986-07-11 Toyama Chem Co Ltd 新規な５−フルオロ−２′−デオキシウリジン−５′−ホスフエ−ト誘導体およびその塩
US4619794A (en) 1982-02-17 1986-10-28 Ciba-Geigy Corporation Spontaneous preparation of small unilamellar liposomes
US4705651A (en) 1984-10-29 1987-11-10 Istituto Gentili S.P.A. Process for the preparation of diphosphonic acids
EP0253412A2 (fr) 1986-07-18 1988-01-20 Ceskoslovenska akademie ved Dérivés N-phosphonométhoxyalkyliques de bases de pyrimidine et de purine, leur procédé de préparation, compositions pharmaceutiques les contenant avec activité antivirale
US4870063A (en) 1985-12-12 1989-09-26 Leo Pharmaceutical Products Ltd. A/S Bisphosphonic acid derivatives, their production and use
US4927814A (en) 1986-07-11 1990-05-22 Boehringer Mannheim Gmbh Diphosphonate derivatives, pharmaceutical compositions and methods of use
WO1991005558A1 (fr) 1989-10-19 1991-05-02 Boehringer Mannheim Gmbh Emploi d'analogues de lecithine comme medicaments anti-viraux ainsi que nouveaux composes
WO1991009602A2 (fr) 1989-12-23 1991-07-11 Boehringer Mannheim Gmbh Utilisation d'alkylphospholipides comme medicaments antiviraux, ainsi que nouveaux composes
US5043437A (en) 1987-12-29 1991-08-27 Khorlin Alexandr A 5'phosphonates of 3'-azido-2',3'dideoxynucleosides
US5047533A (en) 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5196409A (en) 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5247085A (en) 1987-11-30 1993-09-21 Beecham Group P.L.C. Antiviral purine compounds
US5300671A (en) 1989-10-12 1994-04-05 Boehringer Mannheim Italia S.P.A. Gem-diphosphonic acids, and pharmaceutical compositions containing them
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
US5312954A (en) 1989-08-20 1994-05-17 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bis- and tetrakis-phosphonates useful for treating calcium related disorders
EP0632048A1 (fr) 1993-06-29 1995-01-04 Mitsubishi Chemical Corporation Dérivés esters phosphoniques de nucléotides
US5395826A (en) 1992-12-02 1995-03-07 Hoechst Aktiengesellschaft Guanidinealkyl-1,1-bisphosphonic acid derivatives, process for their preparation and their use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5428181A (en) 1991-12-26 1995-06-27 Hoechst Japan Limited Bisphosphonate derivative
WO1995020980A1 (fr) 1994-02-02 1995-08-10 The Regents Of The University Of California Procede permettant d'accroitre la biodisponibilite des compositions pharmaceutiques administrees par voie orale
US5442101A (en) 1990-12-20 1995-08-15 Leiras Oy Methylenebisphosphonic acid derivatives
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5476938A (en) 1990-08-10 1995-12-19 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Process for the preparation of nucleotides
US5484911A (en) 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
US5512671A (en) 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
WO1996033200A1 (fr) 1995-04-21 1996-10-24 Ústav Organické Chemie A Biochemie Akademie Ved C^¿Eské Republiky Nouveaux composes et procedes therapeutiques
WO1996040088A1 (fr) 1995-06-07 1996-12-19 Hostetler Karl Y Derives de l'acyclovir a usage topique
EP0753523A1 (fr) 1995-07-10 1997-01-15 Gador S.A. Acides bis-phosphoniques substitués par un groupe amino
US5614548A (en) 1988-10-25 1997-03-25 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5627185A (en) 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5656745A (en) 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5663159A (en) 1990-09-14 1997-09-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
JPH1029998A (ja) 1996-03-27 1998-02-03 Ceca Sa アルキルまたはアシルジアンヒドロ−１，４：３，６−ｄ−グルシトールのリン酸エステルの製造方法とその利用
US5717095A (en) 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
WO1998018810A1 (fr) 1996-10-30 1998-05-07 The University Of Iowa Research Foundation Molecules d'acide nucleique immunostimulantes
US5756711A (en) 1990-08-20 1998-05-26 Boehringer Mannheim Gmbh Phospholipid derivatives of nucleosides and their use as anti-viral medicaments
US5760013A (en) 1996-08-21 1998-06-02 National Science Council Thymidylate analogs and the use thereof
US5770584A (en) 1993-06-10 1998-06-23 Wake Forest University Method of treating hepatitis virus infections
US5780617A (en) 1990-05-29 1998-07-14 Nexstar Pharmaceuticals, Inc. Synthesis of liponucleotides
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
WO1998038202A1 (fr) 1997-02-28 1998-09-03 Dana-Farber Cancer Institute Promedicaments au phosphonate antiviraux de nucleosides et d'analogues de nucleosides
US5817638A (en) 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5840716A (en) 1996-01-18 1998-11-24 Mitsubishi Chemical Corporation Phosphonate nucleotide compounds
US5856314A (en) 1992-05-29 1999-01-05 The Procter & Gamble Company Thio-substituted, Nitrogen-containing, heterocyclic phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism
US5869468A (en) 1994-04-04 1999-02-09 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs
EP0897709A1 (fr) 1996-12-19 1999-02-24 Kao Corporation Composition de revetement pour les dents
WO1999008685A1 (fr) 1997-08-18 1999-02-25 Queen's University At Kingston Composes de phosphono-carboxylate conçus pour le traitement de l'amylose
US5877166A (en) 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
US5886179A (en) 1993-09-17 1999-03-23 Gilead Sciences, Inc. Nucleotide analogs
US5885973A (en) 1995-12-27 1999-03-23 Gador, S.A. Bone mass anabolic composition comprising olpadronate
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5922696A (en) 1993-04-01 1999-07-13 Merrell Pharmaceuticals Inc. Ethylenic and allenic phosphonate derivatives of purines
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US5962437A (en) 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
WO2000004032A1 (fr) 1998-07-16 2000-01-27 Pierre Fabre Medicament Phosphonates insatures derives d'indole
WO2000006588B1 (fr) 1998-07-27 2000-04-06 Univ Iowa Res Found STEREO-ISOMERES D'OLIGONUCLEOTIDES DE TYPE CpG ET PROCEDES CONNEXES
WO2000037477A1 (fr) 1998-12-22 2000-06-29 Jomaa Pharmaka Gmbh Composes organophosphoriques et leur utilisation
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6225292B1 (en) 1997-06-06 2001-05-01 The Regents Of The University Of California Inhibitors of DNA immunostimulatory sequence activity
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
WO2001012223A3 (fr) 1999-08-19 2001-09-20 Dynavax Tech Corp Procedes de modulation d'une reponse immunitaire par utilisation de sequences immunostimulantes et compositions utilisees
WO2001022990A3 (fr) 1999-09-27 2001-10-04 Coley Pharm Group Inc Methodes concernant l'interferon induit par acides nucleiques immunostimulateur
WO2000021556A9 (fr) 1998-10-09 2001-10-04 Dynavax Tech Corp Compositions anti-hiv comprenant des polynucleotides immunostimulants et des antigenes hiv
WO2001039724A3 (fr) 1999-12-03 2001-10-18 Univ California San Diego Composes de phosphonate
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
WO2003030934A2 (fr) 2001-10-06 2003-04-17 Merial Limited Formulations cpg et procedes y relatifs
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO2003049746A2 (fr) 2001-12-12 2003-06-19 Tibotec Pharmaceuticals Ltd. Combinaison d'inhibiteurs de protease dependant du cytochrome p450
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
US6635472B1 (en) 1997-08-15 2003-10-21 Rubicon Laboratory, Inc. Retrovirus and viral vectors
US20030211072A1 (en) 2000-01-18 2003-11-13 Begona Carreno-Gomez Compositions with enhanced oral bioavailability
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US20040022873A1 (en) 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
EP1438962A1 (fr) 2001-10-23 2004-07-21 Ono Pharmaceutical Co., Ltd. Medicaments comprenant une combinaison de derives de triazaspiro 5,5]undecane et d'un inhibiteur 3a4 d'isoenzyme p450 cytochrome et/ou d'un inhibiteur de p-glycoproteine
WO2004062600A2 (fr) 2003-01-08 2004-07-29 Lectec Corporation Patch antiviral
US20040161398A1 (en) 2000-10-19 2004-08-19 University Of North Carolina At Chapel Hill Compositions and methods for targeting cancer cells
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US20040259845A1 (en) 1995-08-07 2004-12-23 Wake Forest University Lipid analogs for treating viral infections
WO2004112718A3 (fr) 2003-06-20 2005-04-07 Viropharma Inc Composes, compositions et procedes permettant de traiter et de prevenir des infections a orthopoxvirus et des maladies associees
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
WO2005087788A2 (fr) 2004-03-04 2005-09-22 The Regents Of The University Of California Elaboration de phorphonates-esters nucleosidiques
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US20050267217A1 (en) 2000-01-28 2005-12-01 Samuel Baron Methods and devices for preventing transmission of sexually transmitted diseases
WO2005121378A2 (fr) 2004-06-03 2005-12-22 Saint Louis University Methodes et compositions de vaccination
WO2006017044A2 (fr) 2004-07-09 2006-02-16 Gilead Sciences, Inc. Formulations antivirales topiques
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US20060128692A1 (en) 2002-04-26 2006-06-15 Gilead Sciences, Inc Non nucleoside reverse transcriptase inhibitors
WO2006066074A2 (fr) 2004-12-16 2006-06-22 The Regents Of The University Of California Medicaments destines au poumon
WO2006076015A2 (fr) 2004-04-30 2006-07-20 The Regents Of The University Of California 1-[2-(phosphonomethoxy)ethyl]-cytosine et ses analogues
CN1810816A (zh) 2006-03-07 2006-08-02 中国医学科学院医药生物技术研究所 一组具有抑制hiv－1/hbv病毒复制活性的替诺福韦单酯化合物
WO2006110655A2 (fr) 2005-04-08 2006-10-19 Chimerix, Inc. Composes, compositions et methodes de traitement des infections a poxvirus
WO2006110656A2 (fr) 2005-04-08 2006-10-19 Chimerix, Inc. Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
US20060263355A1 (en) 2005-02-28 2006-11-23 Joanne Quan Treatment of bone disorders
WO2001022972A9 (fr) 1999-09-25 2006-12-14 Univ Iowa Res Found Acides nucleiques immunostimulateurs
WO2006130217A3 (fr) 2005-04-01 2007-03-01 Univ California Esters de phosphate de phosphonates de nucleosides substitues
US7288265B1 (en) 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
WO2007130783A2 (fr) 2006-05-03 2007-11-15 Chimerix, Inc. Esters d'alcoxyalkyle de phosphonates, et de phosphonates et de phosphates nucléosidiques antiviraux et antiprolofératifs métaboliquement stables
US20080020018A1 (en) 2004-09-27 2008-01-24 Joey Moodley Combination Products
WO2008033466A2 (fr) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions et procédés pour le traitement de maladies virales
EP1914237A2 (fr) 1999-12-03 2008-04-23 The Regents of The University of California at San Diego Composés antiviraux de ester de phosphonate
US7390791B2 (en) 2000-07-21 2008-06-24 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues
WO2008007392A3 (fr) 2006-07-12 2008-07-17 Matrix Lab Ltd Procédé amélioré destiné à préparer du ténofovir
WO2008118013A2 (fr) 2007-03-23 2008-10-02 To-Bbb Holding B.V. Administration intracellulaire ciblée d'agents antiviraux
WO2008133982A2 (fr) 2007-04-27 2008-11-06 Lectec Corporation Timbre adhésif contenant un agent aversif
WO2008133966A1 (fr) 2007-04-27 2008-11-06 Chimerix, Inc. Procédés de réduction de la néphrotoxicité chez des sujets auxquels il a été administré un nucléoside
WO2008144743A1 (fr) 2007-05-21 2008-11-27 Saint Louis University Outil de criblage d'agents antiviraux
US20090111774A1 (en) 2007-06-01 2009-04-30 Luitpold Pharmaceuticals, Inc. Pmea lipid conjugates
WO2009082819A1 (fr) 2008-01-03 2009-07-09 Virochem Pharma Inc. Nouveaux dérivés de lupane
WO2009082818A1 (fr) 2008-01-03 2009-07-09 Virochem Pharma Inc. Préparation de nouveaux dérivés de c-21-céto lupane et leur utilisation
US7652001B2 (en) 2004-02-05 2010-01-26 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2011011519A1 (fr) 2009-07-21 2011-01-27 Chimerix, Inc. Composés, compositions et procédés pour traiter des troubles oculaires
WO2011017253A1 (fr) 2009-08-03 2011-02-10 Chimerix, Inc. Composition et méthodes de traitement des infections virales et des tumeurs d'origine virale
WO2011053812A1 (fr) 2009-10-30 2011-05-05 Chimerix, Inc. Procédés de traitement de maladies associées à des virus
US20130035313A1 (en) 2010-02-12 2013-02-07 Merrick Almond Nucleoside Phosphonate Salts

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
JP2002516858A (ja) 1998-06-03 2002-06-11 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
AU4225499A (en) 1998-06-03 1999-12-20 Merck & Co., Inc. Hiv integrase inhibitors
WO2000036132A1 (fr) 1998-12-14 2000-06-22 Merck & Co., Inc. Inhibiteurs de vih integrase
WO2000039086A1 (fr) 1998-12-25 2000-07-06 Shionogi & Co., Ltd. Composes heterocycliques aromatiques possedant des activites inhibitrices de l'integrase du vih
EP1186599A4 (fr) 1999-06-02 2003-02-26 Shionogi & Co Nouveau procede de preparation de derives de propenone a substitution
JP2003503386A (ja) 1999-06-25 2003-01-28 メルク エンド カムパニー インコーポレーテッド １−（芳香族またはヘテロ芳香族置換）−３−（ヘテロ芳香族置換）−１，３−プロパンジオン類およびそれの使用
US6245806B1 (en) 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
JP2003510271A (ja) 1999-09-24 2003-03-18 シャイアー・バイオケム・インコーポレイテッド ヌクレオシドアナログを使用したウィルス感染の処置または予防のための方法
AU8009900A (en) 1999-10-13 2001-04-23 Merck & Co., Inc. Hiv integrase inhibitors
CN1418077A (zh) * 2000-01-28 2003-05-14 德克萨斯大学董事会 预防性传播疾病传播的方法和器具
US6545007B2 (en) 2000-11-17 2003-04-08 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
WO2002036734A2 (fr) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza- et polyaza-naphtalenyl cetones utiles en tant qu'inhibiteurs de l'integrase du vih
DE60138635D1 (de) 2000-10-12 2009-06-18 Merck & Co Inc Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase
WO2002030426A1 (fr) 2000-10-12 2002-04-18 Merck & Co., Inc. Azanaphthalenylcarboxamides et polyazanaphthalenylcarboxamides utiles en tant qu'inhibiteurs de la vih integrase
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
AU2003210659A1 (en) 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
WO2004096807A2 (fr) 2003-04-28 2004-11-11 Tibotec Pharmaceuticals Ltd. Inhibiteurs d'integrase vih
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200533358A (en) 2004-02-17 2005-10-16 Anadys Pharmaceuticals Inc Nucleoside phosphonate derivatives useful in the treatment of hiv infections
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
US20070072831A1 (en) 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
CA2653374A1 (fr) 2006-07-07 2008-01-24 Manoj C. Desai Modulateurs de proprietes pharmacocinetiques d'agents therapeutiques

Patent Citations (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1944530A (en) 1929-04-08 1934-01-23 Ig Farbenindustrie Ag Phosphoric acid esters
US3422021A (en) 1963-03-18 1969-01-14 Procter & Gamble Detergent composition
US3468935A (en) 1964-11-11 1969-09-23 Albright & Wilson Mfg Ltd Preparation of organophosphonic acids
GB1280788A (en) 1970-02-27 1972-07-05 Thomae Gmbh Dr K 3-octadecyloxypropyl-2'-trimethylammonium-ethyl phosphate
US4327039A (en) 1979-10-27 1982-04-27 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Process for the production of 3-amino-1-hydroxypropane-1,1-diphosphonic acid
US4444766A (en) 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
CS220713B1 (cs) 1981-06-02 1983-04-29 Antonin Holy Dialkylestery kyseliny p-toluensulfonyloxymethanfosfonové a způsob jejich přípravy
US4619794A (en) 1982-02-17 1986-10-28 Ciba-Geigy Corporation Spontaneous preparation of small unilamellar liposomes
US4562179A (en) 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
US5047533A (en) 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
US4705651A (en) 1984-10-29 1987-11-10 Istituto Gentili S.P.A. Process for the preparation of diphosphonic acids
EP0186405A2 (fr) 1984-12-21 1986-07-02 The Procter & Gamble Company Compositions pharmaceutiques contenant des diphosphonates géminaux
JPS61152694A (ja) 1984-12-27 1986-07-11 Toyama Chem Co Ltd 新規な５−フルオロ−２′−デオキシウリジン−５′−ホスフエ−ト誘導体およびその塩
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US4870063A (en) 1985-12-12 1989-09-26 Leo Pharmaceutical Products Ltd. A/S Bisphosphonic acid derivatives, their production and use
US4927814A (en) 1986-07-11 1990-05-22 Boehringer Mannheim Gmbh Diphosphonate derivatives, pharmaceutical compositions and methods of use
US5142051A (en) 1986-07-18 1992-08-25 Ceskoslovenska Akademie Ved N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases and a therapeutical composition therefrom with antiviral activity
EP0253412A2 (fr) 1986-07-18 1988-01-20 Ceskoslovenska akademie ved Dérivés N-phosphonométhoxyalkyliques de bases de pyrimidine et de purine, leur procédé de préparation, compositions pharmaceutiques les contenant avec activité antivirale
US5854228A (en) 1986-11-18 1998-12-29 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5247085A (en) 1987-11-30 1993-09-21 Beecham Group P.L.C. Antiviral purine compounds
US5043437A (en) 1987-12-29 1991-08-27 Khorlin Alexandr A 5'phosphonates of 3'-azido-2',3'dideoxynucleosides
US5817638A (en) 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5614548A (en) 1988-10-25 1997-03-25 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5744592A (en) 1989-06-28 1998-04-28 Nexstar Pharmaceuticals, Inc. Lipid prodrugs for oral administration
US5827831A (en) 1989-06-28 1998-10-27 Nexstar Pharmaceuticals, Inc. Lipid nucleotide analog prodrugs for oral administration
US5484809A (en) 1989-06-28 1996-01-16 Vestar, Inc. Prodrugs for oral administration containing taxol or substituted taxol covalently bound to a phospholipid
US5196409A (en) 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
US5312954A (en) 1989-08-20 1994-05-17 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bis- and tetrakis-phosphonates useful for treating calcium related disorders
US5300671A (en) 1989-10-12 1994-04-05 Boehringer Mannheim Italia S.P.A. Gem-diphosphonic acids, and pharmaceutical compositions containing them
WO1991005558A1 (fr) 1989-10-19 1991-05-02 Boehringer Mannheim Gmbh Emploi d'analogues de lecithine comme medicaments anti-viraux ainsi que nouveaux composes
US5744461A (en) 1989-11-22 1998-04-28 Nexstar Pharmaceuticals, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991009602A2 (fr) 1989-12-23 1991-07-11 Boehringer Mannheim Gmbh Utilisation d'alkylphospholipides comme medicaments antiviraux, ainsi que nouveaux composes
US5780617A (en) 1990-05-29 1998-07-14 Nexstar Pharmaceuticals, Inc. Synthesis of liponucleotides
US5476938A (en) 1990-08-10 1995-12-19 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Process for the preparation of nucleotides
US5591852A (en) 1990-08-10 1997-01-07 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Process for the preparation of nucleotides
US5756711A (en) 1990-08-20 1998-05-26 Boehringer Mannheim Gmbh Phospholipid derivatives of nucleosides and their use as anti-viral medicaments
US5792756A (en) 1990-09-14 1998-08-11 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5663159A (en) 1990-09-14 1997-09-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5442101A (en) 1990-12-20 1995-08-15 Leiras Oy Methylenebisphosphonic acid derivatives
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5532226A (en) 1991-07-18 1996-07-02 Ortho Pharmaceutical Corporation Trifluoromethybenzylphosphonates useful in treating osteoporosis
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
US5428181A (en) 1991-12-26 1995-06-27 Hoechst Japan Limited Bisphosphonate derivative
US5856314A (en) 1992-05-29 1999-01-05 The Procter & Gamble Company Thio-substituted, Nitrogen-containing, heterocyclic phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism
US5395826A (en) 1992-12-02 1995-03-07 Hoechst Aktiengesellschaft Guanidinealkyl-1,1-bisphosphonic acid derivatives, process for their preparation and their use
US5512671A (en) 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
US5922696A (en) 1993-04-01 1999-07-13 Merrell Pharmaceuticals Inc. Ethylenic and allenic phosphonate derivatives of purines
US5484911A (en) 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
US6030960A (en) 1993-06-10 2000-02-29 Wake Forest University Method of treating hepatitis virus infections
US5770584A (en) 1993-06-10 1998-06-23 Wake Forest University Method of treating hepatitis virus infections
EP0632048A1 (fr) 1993-06-29 1995-01-04 Mitsubishi Chemical Corporation Dérivés esters phosphoniques de nucléotides
US5656745A (en) 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5886179A (en) 1993-09-17 1999-03-23 Gilead Sciences, Inc. Nucleotide analogs
WO1995020980A1 (fr) 1994-02-02 1995-08-10 The Regents Of The University Of California Procede permettant d'accroitre la biodisponibilite des compositions pharmaceutiques administrees par voie orale
US5869468A (en) 1994-04-04 1999-02-09 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5962437A (en) 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
US6002029A (en) 1994-11-15 1999-12-14 Hostetler; Karl Y. Antiviral prodrugs
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US5627185A (en) 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
WO1996033200A1 (fr) 1995-04-21 1996-10-24 Ústav Organické Chemie A Biochemie Akademie Ved C^¿Eské Republiky Nouveaux composes et procedes therapeutiques
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
WO1996040088A1 (fr) 1995-06-07 1996-12-19 Hostetler Karl Y Derives de l'acyclovir a usage topique
EP0753523A1 (fr) 1995-07-10 1997-01-15 Gador S.A. Acides bis-phosphoniques substitués par un groupe amino
US20040259845A1 (en) 1995-08-07 2004-12-23 Wake Forest University Lipid analogs for treating viral infections
US5885973A (en) 1995-12-27 1999-03-23 Gador, S.A. Bone mass anabolic composition comprising olpadronate
US5717095A (en) 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
US5840716A (en) 1996-01-18 1998-11-24 Mitsubishi Chemical Corporation Phosphonate nucleotide compounds
JPH1029998A (ja) 1996-03-27 1998-02-03 Ceca Sa アルキルまたはアシルジアンヒドロ−１，４：３，６−ｄ−グルシトールのリン酸エステルの製造方法とその利用
US5877166A (en) 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
US6043230A (en) 1996-07-26 2000-03-28 Gilead Sciences, Inc. Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
US5977089A (en) 1996-07-26 1999-11-02 Gilead Sciences, Inc. Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
USRE38333E1 (en) 1996-07-26 2003-11-25 Gilead Sciences, Inc. Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
US6069249A (en) 1996-07-26 2000-05-30 Gilead Sciences, Inc. Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5760013A (en) 1996-08-21 1998-06-02 National Science Council Thymidylate analogs and the use thereof
WO1998018810A1 (fr) 1996-10-30 1998-05-07 The University Of Iowa Research Foundation Molecules d'acide nucleique immunostimulantes
EP0897709A1 (fr) 1996-12-19 1999-02-24 Kao Corporation Composition de revetement pour les dents
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
WO1998038202A1 (fr) 1997-02-28 1998-09-03 Dana-Farber Cancer Institute Promedicaments au phosphonate antiviraux de nucleosides et d'analogues de nucleosides
US6225292B1 (en) 1997-06-06 2001-05-01 The Regents Of The University Of California Inhibitors of DNA immunostimulatory sequence activity
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US6635472B1 (en) 1997-08-15 2003-10-21 Rubicon Laboratory, Inc. Retrovirus and viral vectors
WO1999008685A1 (fr) 1997-08-18 1999-02-25 Queen's University At Kingston Composes de phosphono-carboxylate conçus pour le traitement de l'amylose
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO2000004032A1 (fr) 1998-07-16 2000-01-27 Pierre Fabre Medicament Phosphonates insatures derives d'indole
WO2000006588B1 (fr) 1998-07-27 2000-04-06 Univ Iowa Res Found STEREO-ISOMERES D'OLIGONUCLEOTIDES DE TYPE CpG ET PROCEDES CONNEXES
WO2000021556A9 (fr) 1998-10-09 2001-10-04 Dynavax Tech Corp Compositions anti-hiv comprenant des polynucleotides immunostimulants et des antigenes hiv
WO2000037477A1 (fr) 1998-12-22 2000-06-29 Jomaa Pharmaka Gmbh Composes organophosphoriques et leur utilisation
WO2001012223A3 (fr) 1999-08-19 2001-09-20 Dynavax Tech Corp Procedes de modulation d'une reponse immunitaire par utilisation de sequences immunostimulantes et compositions utilisees
WO2001022972A9 (fr) 1999-09-25 2006-12-14 Univ Iowa Res Found Acides nucleiques immunostimulateurs
WO2001022990A3 (fr) 1999-09-27 2001-10-04 Coley Pharm Group Inc Methodes concernant l'interferon induit par acides nucleiques immunostimulateur
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7790703B2 (en) 1999-12-03 2010-09-07 The Regents Of The University Of California Phosphonate compounds
US7098197B2 (en) 1999-12-03 2006-08-29 The Regents Of The University Of California Phosphonate compounds
US20040019232A1 (en) 1999-12-03 2004-01-29 Hostetler Karl Y. Phosphonate compounds
US7034014B2 (en) 1999-12-03 2006-04-25 The Regents Of The University Of California Phosphonate compounds
US6716825B2 (en) 1999-12-03 2004-04-06 The Regents Of The University Of California Phosphonate compounds
WO2001039724A3 (fr) 1999-12-03 2001-10-18 Univ California San Diego Composes de phosphonate
EP1914237A2 (fr) 1999-12-03 2008-04-23 The Regents of The University of California at San Diego Composés antiviraux de ester de phosphonate
US20100173870A1 (en) 1999-12-03 2010-07-08 The Regents Of The University Of California Phosphonate Compounds
US7094772B2 (en) 1999-12-03 2006-08-22 The Regents Of The University Of California Phosphonate compounds
US7452898B2 (en) 1999-12-03 2008-11-18 The Regents Of The University Of California Phosphonate compounds
US20030211072A1 (en) 2000-01-18 2003-11-13 Begona Carreno-Gomez Compositions with enhanced oral bioavailability
US20050267217A1 (en) 2000-01-28 2005-12-01 Samuel Baron Methods and devices for preventing transmission of sexually transmitted diseases
US7390791B2 (en) 2000-07-21 2008-06-24 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues
US7288265B1 (en) 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
US20070026056A1 (en) 2000-10-16 2007-02-01 Lectec Corporation Antiviral patch
US20040161398A1 (en) 2000-10-19 2004-08-19 University Of North Carolina At Chapel Hill Compositions and methods for targeting cancer cells
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
WO2003030934A2 (fr) 2001-10-06 2003-04-17 Merial Limited Formulations cpg et procedes y relatifs
EP1438962A1 (fr) 2001-10-23 2004-07-21 Ono Pharmaceutical Co., Ltd. Medicaments comprenant une combinaison de derives de triazaspiro 5,5]undecane et d'un inhibiteur 3a4 d'isoenzyme p450 cytochrome et/ou d'un inhibiteur de p-glycoproteine
US20040022873A1 (en) 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
WO2003049746A2 (fr) 2001-12-12 2003-06-19 Tibotec Pharmaceuticals Ltd. Combinaison d'inhibiteurs de protease dependant du cytochrome p450
US20060128692A1 (en) 2002-04-26 2006-06-15 Gilead Sciences, Inc Non nucleoside reverse transcriptase inhibitors
WO2004062600A2 (fr) 2003-01-08 2004-07-29 Lectec Corporation Patch antiviral
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
WO2004112718A3 (fr) 2003-06-20 2005-04-07 Viropharma Inc Composes, compositions et procedes permettant de traiter et de prevenir des infections a orthopoxvirus et des maladies associees
US7652001B2 (en) 2004-02-05 2010-01-26 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
WO2005087788A2 (fr) 2004-03-04 2005-09-22 The Regents Of The University Of California Elaboration de phorphonates-esters nucleosidiques
WO2006076015A2 (fr) 2004-04-30 2006-07-20 The Regents Of The University Of California 1-[2-(phosphonomethoxy)ethyl]-cytosine et ses analogues
WO2005121378A2 (fr) 2004-06-03 2005-12-22 Saint Louis University Methodes et compositions de vaccination
US20090087451A1 (en) 2004-06-03 2009-04-02 Saint Louis University Methods and Compositions for Vaccination
WO2006017044A2 (fr) 2004-07-09 2006-02-16 Gilead Sciences, Inc. Formulations antivirales topiques
US20080020018A1 (en) 2004-09-27 2008-01-24 Joey Moodley Combination Products
WO2006066074A2 (fr) 2004-12-16 2006-06-22 The Regents Of The University Of California Medicaments destines au poumon
US20060263355A1 (en) 2005-02-28 2006-11-23 Joanne Quan Treatment of bone disorders
WO2006130217A3 (fr) 2005-04-01 2007-03-01 Univ California Esters de phosphate de phosphonates de nucleosides substitues
WO2006110655A2 (fr) 2005-04-08 2006-10-19 Chimerix, Inc. Composes, compositions et methodes de traitement des infections a poxvirus
US20070003608A1 (en) 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
WO2006110656A2 (fr) 2005-04-08 2006-10-19 Chimerix, Inc. Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
US20070003516A1 (en) 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of poxvirus infections
CN1810816A (zh) 2006-03-07 2006-08-02 中国医学科学院医药生物技术研究所 一组具有抑制hiv－1/hbv病毒复制活性的替诺福韦单酯化合物
US7749983B2 (en) 2006-05-03 2010-07-06 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
US20080009462A1 (en) 2006-05-03 2008-01-10 Chimerix, Inc. Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates
WO2007130783A2 (fr) 2006-05-03 2007-11-15 Chimerix, Inc. Esters d'alcoxyalkyle de phosphonates, et de phosphonates et de phosphates nucléosidiques antiviraux et antiprolofératifs métaboliquement stables
WO2008007392A3 (fr) 2006-07-12 2008-07-17 Matrix Lab Ltd Procédé amélioré destiné à préparer du ténofovir
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
WO2008033466A2 (fr) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions et procédés pour le traitement de maladies virales
WO2008118013A2 (fr) 2007-03-23 2008-10-02 To-Bbb Holding B.V. Administration intracellulaire ciblée d'agents antiviraux
WO2008133966A1 (fr) 2007-04-27 2008-11-06 Chimerix, Inc. Procédés de réduction de la néphrotoxicité chez des sujets auxquels il a été administré un nucléoside
WO2008133982A2 (fr) 2007-04-27 2008-11-06 Lectec Corporation Timbre adhésif contenant un agent aversif
US20090017448A1 (en) 2007-05-21 2009-01-15 Saint Louis University Screening tool for antiviral agents
WO2008144743A1 (fr) 2007-05-21 2008-11-27 Saint Louis University Outil de criblage d'agents antiviraux
US20090111774A1 (en) 2007-06-01 2009-04-30 Luitpold Pharmaceuticals, Inc. Pmea lipid conjugates
WO2009082818A1 (fr) 2008-01-03 2009-07-09 Virochem Pharma Inc. Préparation de nouveaux dérivés de c-21-céto lupane et leur utilisation
WO2009082819A1 (fr) 2008-01-03 2009-07-09 Virochem Pharma Inc. Nouveaux dérivés de lupane
WO2011011519A1 (fr) 2009-07-21 2011-01-27 Chimerix, Inc. Composés, compositions et procédés pour traiter des troubles oculaires
WO2011017253A1 (fr) 2009-08-03 2011-02-10 Chimerix, Inc. Composition et méthodes de traitement des infections virales et des tumeurs d'origine virale
WO2011053812A1 (fr) 2009-10-30 2011-05-05 Chimerix, Inc. Procédés de traitement de maladies associées à des virus
US20130035313A1 (en) 2010-02-12 2013-02-07 Merrick Almond Nucleoside Phosphonate Salts

Non-Patent Citations (93)

* Cited by examiner, † Cited by third party
Title
"Creating Orally Available Medicines from Bioactive Molecules." Presentation at BIG 2004 Annual International Convention. (Jun. 7, 2004).
Aldern et al. "Increased Antiviral Activity of 1-O-Hexadecyloxypropyl-[2-14C]Cidofovir in MRC-5 Human Lung Fibroblasts is Explained by Unique Cellular Uptake and Metabolism." Mol. Pharmacol. 63.3(2003):678-681.
Andrei et al. "Activities of Various Compounds against Murine and Primate Polyomaviruses." Antimicrob. Agents Chemother. 41.3(1997):587-593.
Annaert et al. "In Vitro, Ex Vivo, and In Situ Intestinal Absorption Characteristics of the Antiviral Ester Prodrug Adefovir Dipivoxil." J. Pharm. Sci. 89.8(2000):1054-1062.
Balzarini et al. "Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates." Antimicrob. Agents Chemother. 45.7(2002):2185-2193.
Bartlett et al. "Phase I Trial of Doxorubicin with Cyclosporine as a Modulator of Multidrug Resistance." J. Clin. Oncol. 12.4(1994):835-842.
Beadle et al. "Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Mutiple-Log Enhancement of Antiviral Activity Against Cytomegalovirus and Herpes Virus Replication In Vitro." Antimicrob Agents Chemother. 46.8(2002):2381-2386.
Berge et al. "Pharmaceutical Salts." J. Pharmaceutical Sci. 66.1(1977):1-19.
Bidanset et al. "Oral Activity of Ether Lipid Ester Prodrugs of Cidofovir against Experimental Human Cytomegalovirus Infection." J. Infect. Dis. 190.3(2004):499-503.
Biron. "Antiviral Drugs for Cytomegalovirus Diseases." Antiviral Res. 71(2006):154-163.
Blasco et al. "Extracellular Vaccinia Virus Formation and Cell-to-Cell Virus Transmission are Prevented by Deletion of the Gene Encoding the 37,000-Dalton Outer Envelope Protein." J. Virol. 65.11(1991):5910-5920.
Borroto-Esoda, K. et al., "In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine, "Antiviral Therapy, vol. 11, No. 3, Jan. 1, 2006, pp. 377-384.
Bray et al. "Antiviral Prophylaxis of Smallpox." J. Antimicrob. Chemother. 54.1(2004):1-5.
Buller et al. "Efficacy of Oral Active Ether Lipid Analogs of Cidofovir in a Lethal Mousepox Model." Virol. 318.2(2004):474-481.
Buller et al. "Efficacy of Smallpox Vaccination in the Presence of Antiviral Drugs, Cidofovir, and Hexadecyoxypropylcidofovir." Antiviral Res. 65.3(2005):A80. (Abstract #72).
Ciesla et al. "Esterification of Cidofovir with Alkoxyalkanols Increases Oral Bioavailability and Diminishes Drug Accumulation in Kidney." Antiviral Res. 59.3(2003):163-171.
Cihlar, T. et al., "Design and Profiling of GS-9148, a Novel Nucloetide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131, " Antimicrobial Agents and Chemotherapy, vol. 52, Feb. 2008, p. 655-665.
Collier "Efficacy of combination antiviral therapy, Advance in Experimental Medicine and Biology," 1996, vol. 394, pp. 355-372. *
Connelly et al. "Mechanism of Uptake of the Phosphonate Analog (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl)Cytosine (HPMPC) in Vero Cells." Biochem. Pharma. 46.6(1993):1053-1057.
Dal Pozzo et al. "In Vitro Evaluation of the Anti-orf Virus Activity of Alkoxyalkyl Esters of CDV, cCDV and (S)-HPMPA." Antiviral Res. 75(2007):52-57.
De Clercq et al. "Therapeutic Potential of Nucleoside/Nucleotide Analogues Against Poxvirus Infections." Rev. Med. Virol. 14.5(2004):289-300.
De Clercq. "Antiviral Drugs in Current Clinical Use." J. Virol. 30.2(2004):115-133.
De Clercq. "Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections." Clin. Microbiol. Rev. 16.4(2003):569-596.
De Clercq. "The Acyclic Nucleoside Phosphonates from Inception to Clinical Use: Historical Perspective." Antiviral Res. 75(2007):1-13.
De Clercq. "Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections." Clin. Microbiol. Rev. 14.2(2001):382-397.
Delaney IV, W.E. et al., "Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro," Antimicrobrobial Agents and Chemotherapy, vol. 48, Oct. 2004, p. 3702-3710.
Denes et al. "Main Adult Herpes Virus Infections of the CNS." Anti-Infective Therapy. 3.4(2005):663-678.
Fardis et al. "Case Study: Tenofovir Disoproxil Fumarate: An Oral Prodrug of Tenofovir." Volume V: Prodrugs: Challenges and Rewards Part 1. Biotechnology, Pharmaceutical Aspects. 5.20(2007):649-657.
Fisher et al. "Phase I Trial of Etoposide with the Cyclosporine SDZ PSC 833, a Modulator of Multidrug Resistance (MDR)." Proc. Am Soc. Clin. Oncol. 12(1994):143 (Abstract #368).
Franchetti, P. et al., "Inhibition of HIV-1 Replication in Macrophages by Red Blood Cell-Mediated Delivery of a Heterodinucleotide of Lamivudine and Tenofovir," Nucleosides, Nucleotides, and Nucleic Acids, 26:953-957, 2007.
Fung, H.B. et al., "Tenofovir Disoproxil Fumarate: A Nucleotide Reverse Transcriptase Inhibitor for the Treatment of HIV Infection," Clinical Therapeutics/vol. 24, No. 10, 2002.
Gallant et al. "Tenofovir disoproxil fumarate (Viread} for the treatment of HIV infection," Expert Review of Anti-Infective Therapy, 2003, vol. 1, No. 3, pp. 415-422. *
Gauvry et al. "Dealkylation of Dialkyl Phosphonates with Boron Tribromide." Synthesis. 4(2001):553-554.
Hammond et al. "Alkylglycerol Prodrugs of Phosphonoformate are Potent In Vitro Inhibitors of Nucleoside-Resistant Human Immunodeficiency Virus Type 1 and Select for Resistance Mutations that Suppress Zidovudine Resistance." Antimicrob. Agents Chemother. 45.6(2001):1621-1628.
Hartline et al. "Ether Lipid-Ester Prodrugs of Acyclic Nucleoside Phosphonates: Activity Against Adenovirus Replication In Vitro." J. Infect. Dis. 191.3(2005):396-399.
Held et al. "Treatment of BK Virus-Associated Hemorrhagic Cystitis and Simultaneous CMV Reactivation with Cidofovir." Bone Marrow Transplant. 26(2000):347-350.
Hillenkamp et al. "Topical Treatment of Acute Adenoviral Keratoconjunctivitis With 0.2% Cidofovir and 1% Cyclosporine." Arch. Ophthalmol. 119.10(2001):1487-1491.
Hockova et al. "5-Substituted-2,4-diamino-642-(phosphonomethoxy)ethoxy]pyrimidines-Acyclic Nucleoside Phosphonate Analogues with Antiviral Activity." J. Med. Chem. 46.23(2003):50645073.
Holy et al. "6-[2-(Phosphonomethoxy)alkoxy]pyrimidines With Antiviral Activity." J. Med. Chem. 45.9(2002):1918-1929.
Holy et al. "Structure-Antiviral Activity Relationship in the Series of Pyrimidine and Purine N[2(2-Phosphonomethoxy)ethyl] Nucleotide Analogues." J. Med. Chem. 42.12(1999):2064-2086.
Holy. "Phosphonomethoxyalkyl Analogs of Nucleotides." Curr. Pharma Des. 9.31(2003):2567-2592.
Holy. "Simple Method for Cleavage of Phosphonic Acid Diesters to Monoesters." Synthesis. 4(1998):381-385.
Hostetler et al. "Enhanced Antiproliferative Effects of Alkozyalkyl Esters of Cidofovir in Human Cervical Cancers Cells in vitro." Mol. Cancer Ther. 5.1(2005):156-159.
Hostetler, K., "In vitro and in vivo evaluation of hexadecyloxypropyl-9-R-[2-(phosphono-methoxy) propyl]adenine as a potential treatment of HIV-1 infection", Global Antiviral Journal, Abstract 84, 2(2):96-97 (2006).
Hostetler, K.Y. et al., "Alkoxyalkyl Esters of (S)-9-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]Adenine Are Potent Inhibitors of the Replication of Wild-Type and Drug-Resistant Human Immunodeficiency Virus Type 1 In Vitro", Antimicrobial Agents and Chemotherapy, 50(8):2875-2879 (2006).
Hostetler. "Alkoxyalkyl Prodrugs of Acyclic Nucleoside Phosphonates Enchance Oral Antiviral Activity and Reduce Toxicity: Current State of the Art." Antiviral Research. 82.2(2009):A84-A98.
Huggins et al. "Cidofovir Treatment of Variola (Smallpox) in the Hemorrhagic Smallpox Primate Model and the IV Monkeypox Primate Model." Antiviral Res. 57.3(2003):A78. (Abstract #127).
Huggins et al. "Orally Active Ether Lipid Prodrugs of Cidofovir for the Treatment of Smallpox." Antiviral Res. 53(2002):A66. (Abstract #104).
Huggins et al. "Successful Cidofovir Treatment of Smallpox-Like Disease in Variola and Monkeypox Primate Models." Antiviral Res. 62.2(2004):A57-A58. (Abstract #76).
International Search Report for corresponding PCT application No. PCT/US2009/000447, mail date Jul. 29, 2009.
Jacobson. "Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome." Drug Ther. 337(1997):105-114.
Jasko et al. "A New Approach to Synthesis of 5'-)-phosphonomethyl Derivatives of Nucleosides and Their Analogues." Bioorganicheskaya Khimiya. 20.1(1994):50-54. (English Abstract Only).
Josephson et al. "Polyomavirus-Associated Nephropathy: Update on Antiviral Strategies." Transpl. Infect. Dis. 8(2006):95-101.
Kearney et al. "Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics." Clin. Pharmacokinet. 43.9(2004):595-612.
Keith et al. "Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication." Antimicrob Agents Chemother. 47.7(2003):2193-2198.
Keith et al. "Inhibitory Activity of Alkoxyalkyl and Alkyl Esters of Cidofovir and Cyclic Cidofovir Against Orthopoxvirus Replication In Vitro." Antimicrob. Agents Chemother. 48.5(2004):1869-1871.
Kern et al. "Enhanced Inhibition of Orthopoxvirus Replication In Vitro by Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir." Antimicrob. Agents Chemother. 46.4(2002):991-995.
Kern et al. "Oral Treatment of Murine Cytomegalovirus Infections with Ether Lipid Esters of Cidofovir." Antimicrob Agents Chemother. 48.9(2004):3516-3522.
Kini et al. "Alkoxy Propane Prodrugs of Foscarnet: Effect of Alkyl Chain Length on in Vitro Antiviral Activity in Cells Infected with HIV-1, HSV-1 and HCMV." Antiviral Res. 36.1(1997):43-53.
Kornbluth et al. "Mutations in the E9L Polymerase Gene of Cidofovir-Resistant Vaccinia Virus Strain WR are Associated with the Drug Resistance Phenotype." Antimicrob. Agents Chemother. 50.12(2006):4038-4043.
Lebeau et al. "Activities of Alkoxyalkyl Esters of Cidofovir (CDV), Cyclic CDV, and (S)-9-(3- Hydroxy-2-Phosphonylmethoxypropyl)Adenine Against Orthopoxviruses in Cell Monolayers and in Organotypic Cultures." Antimicrob. Agents Chemother. 50.7(2006):2525-2529.
Lu et al. "Intraocular Properties of Hexadecyloxypropyl-Cyclic-Cidofovir in Guinea Pigs." J. Ocul. Pharmacol. Ther. 21.3(2005):205-209.
Lyseng-Williamson, K. A. et al., "Tenofovir Disoproxil Fumarate a Review of its Use in the Management of HIV infection," Drugs, 2005, 65 (3), pp: 413-432.
Madeddu et al. "Renal Toxicity in HIV-Infected Patients Receiving HAART Including Tenofovir." lnfez. Med. 14.3(2006):125-134. (Italian Original and English Abstract).
Michaud et al. "The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition." Pharm. Rev. 64.3(2012):803-833.
Myrick, F. et al., "The Trible Combination of Tenofovir, Emtricitabine and Efavirenz Shows Synergistic Anti-HIV-1 Activity In Vitro," Program and Abstracts/Antiviral Research, vol. 74, No. 3, Mar. 27, 2007, p. A61.
Niemi et al. "Bisphosphonate Prodrugs: Synthesis and in Vitro Evaluation of Novel Acyloxyalkyl Esters of Clodronic Acid." J. Med. Chem. 42.24(1999):5053-5058.
Painter et al. "Biochemical and Mechanistic Basis for the Activity of Nucleoside Analogue Inhibitors of HIV Reverse Transcriptase." Curr. Topics Med. Chem. 4.10(2004):1035-1044.
Painter et al. "Design and Development of Oral Drugs for the Prophylaxis and Treatment of Smallpox Infection." Trends Biotechnol. 22.8(2004):423-427.
Painter, G.R. et al., "Evaluation of Hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy) Propyl]-Adenine, CMX157, as a Potential Teatment for Human Immunodeficiency Virus Type 1 and Hepatitus B Virus Infections, "Antimicrobial Agents and Chemotherapy, vol. 51, Oct. 2007, p. 3505-3509.
Parker et al. "Efficacy of Therapeutic Intervention with an Oral Ether-Lipid Analogue of Cidofovir (CMX001) in a Lethal Mousepox Model." Antiviral Res. 77.1(2008):39-49.
Portilla et al. "Progressive Multifocal Leukoencephalopathy Treated with Cidofovir in HIV-Infected Patients Receiving Highly Active Anti-Retroviral Therapy." J. Infect. 41(2000):182-184.
Postma et al. "Cost-effectiveness of antenatal HIV-testing: reviewing its pharmaceutical and methodological aspects," Expert Opin. Pharmacother. 2004, vol. 5, No. 3, pp. 521-528. *
Quenelle et al. "Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of Cidofovir." Antimicrob. Agents Chemother. 48.2(2004):404-412.
Quenelle et al. "Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of Cidofovir." Antimicrob. Agents Chemother. 48.2(2004):404-412. Erratum in: Antimicrob. Agents Chemother. 48.5(2004):1919.
Quenelle et al. "Synergistic Efficacy of the Combination of ST-246 with CMX001 Against Orthopoxviruses." Antimicrob. Agents Chemother. 51.11(2007):4118-4127.
Randhawa et al. "Ether Lipids Ester Derivatives of Cidofovir Inhibit Polyomavirus BK Replication In Vitro." Antimicrob. Agents Chemother. 50.4(2006):1564-1566.
Ray, A.S., "Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine," Antiviral Therapy, vol. 10, No. 3, (2005), pp. 451-457.
Remichkova et al. "Synergistic Combination Effect of Cidofovir and Idoxuridine on Vaccinia Virus Replication." Antiviral Res. 65.3(2005):A80-A81. (Abstract #74).
Rogers. "A General Synthesis of Phosphonic Acid Dichlorides Using Oxalyl Chloride and DMF Catalysis." Tetrahed. Lett. 33.49(1992):7473-7474.
Saady et al. "Direct Esterification of Phosphonic Acid Salts Using the Mitsunobu Reaction." Synlett. 6(1995):643-644.
Smee et al. "A Review of Compounds Exhibiting Anti-Orthopoxvirus Activity in Animal Models." Antiviral Res. 57.1-2(2003):41-52.
Smee et al. "Characterization and Treatment of Cidofovir-Resistant Vaccinia (WR Strain) Virus Infections in Cell Culture and in Mice." Antiviral Chem. Chemother. 16.3(2005):203-211.
Smee et al. "Effects of Four Antiviral Substances on Lethal Vaccinia Virus (IHD Strain) Respiratory Infections in Mice." Int. J. Antimicrob. Agents. 23.5(2004):430-437.
Toth et al. "Hexadcyloxypropyl-Cidofovir, CMX001, Prevents Adenovirus-Induced Mortality in a Permissive, Immunosuppressed Animal Model." PNAS. 105.20(2008):7293-7297.
Wallot et al. "Disseminated Adenovirus Infection with Respiratory Failure in Pediatric Liver Transplant Recipients: Impact of Intravenous Cidofovir and Inhaled Nitric Oxide." Pediatr. Transplantation. 10(2006):121-127.
Wan et al. "Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir: Effects of Alkyl Chain Length, Unsaturation, and Substitution on the in vitro Antiviral Activity in Cells Infected with HSV-1 and HCMV." 224th ACS National Meeting. Boston, MA. Aug. 18-22, 2002. (Abstract #MEDI-30).
Wan et al. "Comparison of the Antiviral Activities of Alkoxyalkyl and Alkyl Esters of Cidofovir Against Human and Murine Cytomegalovirus Replication In Vitro." Antimicrob. Agents Chemother. 49.2(2005):656-662.
Wawzonek et al. "Preparation of Long Chain Alkyl Hydroperoxides." J. Org. Chem. 25.4(1960):621-623.
Williams-Aziz et al. "Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir Against Replication of Herpesviruses in Vitro." Antimicrob. Agents Chemother. 49.9(2005):3724-3733.
Yang et al. "An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge." J. Virol. 79.20(2005):13139-13149.
Zanger et al. "Structure-Activity Relationship and Drug Design." Remington's Pharmaceutical Sciences. (1980):420-435.
Zimmermann et al. "Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions." Clin. Infect. Dis. 42(2006):283-290.

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694024B2 (en) * 2010-04-26 2017-07-04 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
US20160158259A1 (en) * 2010-04-26 2016-06-09 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
US9956239B2 (en) 2010-04-26 2018-05-01 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
US10076533B2 (en) 2013-03-15 2018-09-18 The Regents Of The University Of California Acyclic nucleoside phosphonate diesters
US10449207B2 (en) 2013-03-15 2019-10-22 The Regents Of The University Of California Acyclic nucleoside phosphonate diesters
US9775852B2 (en) 2013-03-15 2017-10-03 The Regents Of The University Of California Acyclic nucleoside phosphonate diesters
US10195222B2 (en) 2013-03-15 2019-02-05 The Regents Of The University Of California Acyclic nucleoside phosphonate diesters
US10076532B2 (en) 2013-03-15 2018-09-18 The Regents Of The University Of California Acyclic nucleoside phosphonate diesters
WO2016044281A1 (fr) 2014-09-15 2016-03-24 The Regents Of The University Of California Analogues nucléotidiques
US9493493B2 (en) 2014-09-15 2016-11-15 The Regents Of The University Of California Nucleotide analogs
US9801884B2 (en) 2014-09-15 2017-10-31 The Regents Of The University Of California Nucleotide analogs
US10213430B2 (en) 2014-09-15 2019-02-26 The Regents Of The University Of California Nucleotide analogs
US10702532B2 (en) 2014-09-15 2020-07-07 The Regents Of The University Of California Nucleotide analogs
US11344555B2 (en) 2014-09-15 2022-05-31 The Regents Of The University Of California Nucleotide analogs
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs
WO2017048956A1 (fr) 2015-09-15 2017-03-23 The Regents Of The University Of California Analogues nucléotidiques
US11014950B2 (en) 2015-09-15 2021-05-25 The Regents Of The University Of California Nucleotide analogs
EP3875462A1 (fr) 2015-09-15 2021-09-08 The Regents of The University of California Analogues nucléotidiques
US11572377B2 (en) 2015-09-15 2023-02-07 The Regents Of The University Of California Nucleotide analogs

Also Published As

Publication number Publication date
CN101977610B (zh) 2012-05-16
ES2572631T3 (es) 2016-06-01
IL207170A0 (en) 2010-12-30
US20110021464A1 (en) 2011-01-27
HK1151237A1 (zh) 2012-01-27
AU2009206673A1 (en) 2009-07-30
CN105055432A (zh) 2015-11-18
HK1225316A1 (zh) 2017-09-08
CA2713105A1 (fr) 2009-07-30
CN102670628B (zh) 2015-11-25
IL207170A (en) 2016-11-30
JP2011510077A (ja) 2011-03-31
WO2009094190A2 (fr) 2009-07-30
AU2009206673B2 (en) 2015-04-23
CN101977610A (zh) 2011-02-16
ZA201005737B (en) 2012-04-25
EP2254582B1 (fr) 2016-01-20
IL242518A (en) 2017-07-31
EP3085377A1 (fr) 2016-10-26
CN102670628A (zh) 2012-09-19
WO2009094190A3 (fr) 2009-10-01
EP2254582A4 (fr) 2011-07-20
CA2713105C (fr) 2016-06-07
WO2009094191A2 (fr) 2009-07-30
WO2009094191A3 (fr) 2009-10-01
MX2010008148A (es) 2010-10-20
JP5562255B2 (ja) 2014-07-30
EP2254582A2 (fr) 2010-12-01

Similar Documents

Publication Publication Date Title
US8993542B2 (en) Methods of treating viral infections
US9765100B2 (en) Nucleoside phosphonate salts
US9956239B2 (en) Methods of treating retroviral infections and related dosage regimes
US20140011769A1 (en) Methods of Treating Retroviral Infections and Related Dosage Regimes

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHIMERIX, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANIER, ERNEST RANDALL;ALMOND, MERRICK R.;PAINTER, GEORGE R.;REEL/FRAME:025096/0673

Effective date: 20100917

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载